tradingkey.logo

Sonoma Pharmaceuticals Inc

SNOA
View Detailed Chart
3.760USD
-0.020-0.53%
Close 11/04, 16:00ETQuotes delayed by 15 min
6.18MMarket Cap
LossP/E TTM

Sonoma Pharmaceuticals Inc

3.760
-0.020-0.53%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.53%

5 Days

-1.83%

1 Month

-5.76%

6 Months

+11.24%

Year to Date

+39.78%

1 Year

+36.73%

View Detailed Chart

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sonoma Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
80 / 159
Overall Ranking
229 / 4616
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Strong Buy
Current Rating
14.800
Target Price
+291.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Sonoma Pharmaceuticals Inc Highlights

StrengthsRisks
Sonoma Pharmaceuticals, Inc. is a global healthcare company, which is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The Company's product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar Gel; Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel; Microcyn OTC Advanced Wound & Skin Cleanser; Podiacyn Advanced Everyday Foot Care, MicrocynAH and others. Lumacyn Clarifying Mist is intended for use as a daily skin toner, to soothe and cleanse the skin, reduce redness, and manage blemishes by reducing infection. Podiacyn is intended for management of foot odors, infections, and irritations, as well as daily foot health and hygiene. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.
Growing
The company is in a growing phase, with the latest annual income totaling USD 14.29M.
Undervalued
The company’s latest PE is -1.71, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 104.13K shares, increasing 18.10% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 18.79K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.01.

Sonoma Pharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Sonoma Pharmaceuticals Inc Info

Sonoma Pharmaceuticals, Inc. is a global healthcare company, which is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The Company's product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar Gel; Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel; Microcyn OTC Advanced Wound & Skin Cleanser; Podiacyn Advanced Everyday Foot Care, MicrocynAH and others. Lumacyn Clarifying Mist is intended for use as a daily skin toner, to soothe and cleanse the skin, reduce redness, and manage blemishes by reducing infection. Podiacyn is intended for management of foot odors, infections, and irritations, as well as daily foot health and hygiene. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.
Ticker SymbolSNOA
CompanySonoma Pharmaceuticals Inc
CEOMs. Amy Trombly
Websitehttps://sonomapharma.com/
KeyAI